End to plan for merger with Presidio follows BioCryst R&D setbacks
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals and Presidio Pharmaceuticals announced merger plans on 18 October to create a company focused on orphan and infectious diseases, with a strong focus on hepatitis C virus (HCV). But before the month was through, the first of at least three negative events for BioCryst had put the pact in jeopardy, and by 30 November the companies terminated their proposed transaction.
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.